Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study

Breast Cancer Research and Treatment · Published 2026-07-01 · DOI 10.1007/s10549-026-08023-2

Authors (23)

Palma Fedele, Alessandro Rizzo, Matteo Landriscina, Luigia Stefania Stucci, Carmela Inneo, Maria Morritti, Franco Morelli, Francesco Giuliani, Lucia Moraca, Giuseppe Cairo, Marianna Giampaglia, Beatrice Tedesco, Assunta Melaccio, Felicia M. Maselli, Antonio Gnoni, Antonella Licchetta, Federica Fumai, Elsa Vitale, Fiorella Restaino Marino, Emanuela Zifarone, Laura Lanotte, Raffaele Ardito, Gennaro Gadaleta-Caldarola

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Fedele, P., Rizzo, A., Landriscina, M., et al. (2026). Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08023-2

Related articles